Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05120947 | Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers(HART-HN) | completed | N/A | 18 | Medical College of WisconsinOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05213884 | The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC | completed | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03621696 | Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"(MINT) | completed | Phase 2 | 63 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03574792 | Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy | completed | Phase 2 | 62 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05077709 | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | completed | Phase 2 | 63 | IO BiotechINDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT02510859 | Nutrition and Life QUality Patients With Head and Neck Cancers(NUQUE2) | completed | N/A | 117 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03370276 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05673577 | Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients | completed | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01783587 | Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | completed | Phase 1 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04188665 | Using MASL to Combat Oral Cancer | completed | Early Phase 1 | 18 | Rowan UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT01612351 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04042935 | Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC | completed | Phase 1 | 5 | University of Colorado, DenverOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03313804 | Priming Immunotherapy in Advanced Disease With Radiation | completed | Phase 2 | 76 | John L. Villano, MD, PhDOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT00939627 | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02031250 | Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer | completed | Phase 2 | 106 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03953976 | INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy | completed | Phase 2 | 67 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03480672 | Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 211 | University of LeipzigOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03993353 | Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 7 | University of California, San DiegoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT01932697 | Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer | completed | Phase 2 | 81 | Mayo ClinicOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04284540 | Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma | completed | N/A | 37 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT03082534 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of California, San DiegoOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03829722 | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | completed | Phase 2 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03978689 | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 80 | Cue BiopharmaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03578406 | HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer | completed | Phase 1 | 9 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05524025 | The SPOT-HPV Study | completed | — | 360 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04139057 | EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC | completed | Phase 1 / Phase 2 | 10 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07337122 | Collagen Matrix in Oral Cancer Surgery | completed | — | 33 | SAYAH CharlineOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04326257 | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | completed | Phase 2 | 20 | Dan ZandbergOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05482880 | Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | completed | — | 78 | Maastricht University Medical CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03896412 | Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma(PERSO-NECK) | completed | N/A | 40 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04031534 | Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma(HYPONECK) | completed | Phase 2 | 16 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04490564 | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma | completed | — | 135 | Pharmassist LtdINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01827956 | Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms(FCR-VADS) | completed | — | 121 | Institut BergoniéOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04811027 | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC(TACTI-003) | completed | Phase 2 | 171 | Immutep S.A.S.INDUSTRY | 9 | Dec 11, 2025 | clinicaltrials |
| NCT03381183 | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06730412 | ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)(Clear-HPVca) | completed | — | 103 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT04725396 | Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC(CURVE) | completed | N/A | 132 | UNICANCEROTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04454489 | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition | completed | Phase 2 | 21 | Wake Forest University Health SciencesOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT02369458 | Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03021993 | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | completed | Phase 2 | 17 | Medical University of South CarolinaOTHER | 1 | Nov 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 1, 2026source: clinicaltrials